- slider1.jpg
- slider1.jpg
TREATING DEADLY INFLAMMATION
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 53 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018
- CytoSorbents to Present at the Cowen 39th Annual Health Care Conference
- CytoSorbents Expands Direct Sales to Poland, the Nordics, and the Netherlands
- CytoSorbents to Report Fiscal 2018 Operating and Financial Results
- CytoSorbents to Participate at the 8th Annual SVB Leerink Global Healthcare Conference
Videos to Watch On The Street - "Cytosorbents CEO on How to Avoid the Flu
and Cytokine Storms" click here
- slider1.jpg
